Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 2Phase 1 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 19Recruiting 8Active not recruiting 8Unknown 7Not yet recruiting 5Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × lenvatinib × Clear all
NCT03744247 2019-05-02

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡